Podcasts about oramed pharmaceuticals

Oramed Pharmaceuticals (ORMP) develops oral drug delivery systems for treatments and vaccines and is today's 360 spotlight. Nadav Kidron, CEO of Oramed Pharmaceuticals gives an overview of the company. He also talks about ORMP has won approval from South African regulators to start a clinical trial of oral Covid-19 vaccine. ORMP is up more than 500% YTD. Tune in to find out more.

Over 422 million people worldwide have diabetes, and this number is growing every year. Most people with diabetes Type 1 will eventually need to be treated with insulin, currently only available as an injection. This is a painful experience as in some cases, it requires multiple finger pricks and insulin injections per day to monitor and keep blood glucose levels within the desired range. But there is good news beckoning on the horizon. Oramed Pharmaceuticals a biotechnology company based in the United States and Israel is developing an oral drug delivery system aptly named Oramed's oral insulin. This could be the first oral insulin available on the market and a game changer in how diabetes is treated.

Bloomberg News Deals Reporter Ed Hammond discusses Novartis, Schwab and LVMH acquisitions. Jake Bright, TechCrunch Contributor, talks about Chinese investment in Africa's tech-ecosystem. Nadav Kidron, CEO at Oramed Pharmaceuticals, explains the development of an insulin pill for the treatment of Type 2 diabetes. Bloomberg Businessweek Editor Joel Weber and Bloomberg News Investing Reporter Annie Massa break down Wall Street wading into sports gambling. And we Drive to the Close with Dryden Pence, CIO at Pence Capital Management. Hosts: Carol Massar and Jason Kelly. Producer: Doni Holloway. Learn more about your ad-choices at https://www.iheartpodcastnetwork.com

Bloomberg News Deals Reporter Ed Hammond discusses Novartis, Schwab and LVMH acquisitions. Jake Bright, TechCrunch Contributor, talks about Chinese investment in Africa’s tech-ecosystem. Nadav Kidron, CEO at Oramed Pharmaceuticals, explains the development of an insulin pill for the treatment of Type 2 diabetes. Bloomberg Businessweek Editor Joel Weber and Bloomberg News Investing Reporter Annie Massa break down Wall Street wading into sports gambling. And we Drive to the Close with Dryden Pence, CIO at Pence Capital Management. Hosts: Carol Massar and Jason Kelly. Producer: Doni Holloway.

Today we're meeting Mark Hasleton, VP Business Development at Oramed Pharmaceuticals and volunteer mentor for Olim (new immigrants to Israel). Mark moved to Israel from the UK 10 years ago and resides in Raanana with his 3 kids. Mark is a great example of how to network yourself to success in Israel. In this interview, Mark answers one simple question: Where would you start if you would have to build a professional network in Israel from scratch?

Nadav Kidron is the CEO & Director of Oramed Pharmaceuticals, which he co-founded in 2006 to bring oral insulin to the millions of people with diabetes. Kidron holds a bachelor’s degree in law and an international MBA. He’s a member of the Israeli Advanced Technology Industries, and an international lecturer on Israel’s entrepreneurial and innovative culture.

Today in FirstWord:

Nadav Kidron, CEO and director of Oramed Pharmaceuticals, discusses his company’s medical breakthrough in adapting insulin so that it can be taken as a pill instead of a shot. Can this technology be used for other kinds of medication? What does this mean for modern medicine?

Featuring: Great Jewish A Capella, news from Israel and Morning Chizuk with Rabbi Dovid Goldwasser. In addition, Nachum got an Oramed Pharmaceuticals update with Nadav Kidron, a Dirshu update with Rabbi Gabi Fried and a Shalom Task Force update with Dr. Alan Singer, Basya Kovacs & Rachel Marks.